Skip to content
Veracuity
VeracuityVeracuity
  • HOME
  • ABOUT
  • SERVICES
    • CONSUMERS
    • MANUFACTURERS
  • CONTACT US
  • BLOG
  • HOME
  • ABOUT
  • SERVICES
    • CONSUMERS
    • MANUFACTURERS
  • CONTACT US
  • BLOG

Drug diversion – issues and identification

UncategorizedBy veracuityJuly 8, 2019Leave a comment

Veracuity Blog Drug diversion – issues and identification Section 505-1 of the FDCA authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS) if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks. Spotting drug diversion within the current reporting system…

Go to Top
Veracuity Logo
  • About
  • Mission
  • Search
  • Report a Side Effect
  • News
  • Site map
  • Register
  • Contact Us
  • © 2021 Veracuity. All Rights Reserved
  • Terms & Conditions
  • Data Privacy
———CopyRightFooter